{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:03:51Z","timestamp":1746335031633,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R34DA035094"],"award-info":[{"award-number":["R34DA035094"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12954-018-0249-3","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T12:44:55Z","timestamp":1535719495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Feasibility of needle and syringe programs in Tajikistan distributing low dead space needles"],"prefix":"10.1186","volume":"15","author":[{"given":"William A.","family":"Zule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisher","family":"Latypov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Otiashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffani","family":"Bangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiy V.","family":"Bobashev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"249_CR1","volume-title":"Three cents a day is not enough: resourcing HIV-related harm reduction on global basis: International Harm Reduction Association (IHRA)","author":"GV Stimson","year":"2010","unstructured":"Stimson GV, Cook C, Bridge J, Rio-Navarro J, Lines R, Barrett D. Three cents a day is not enough: resourcing HIV-related harm reduction on global basis: International Harm Reduction Association (IHRA); 2010."},{"issue":"6 Suppl 2","key":"249_CR2","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1331\/1086-5802.42.0.S13.Burris","volume":"42","author":"S Burris","year":"2002","unstructured":"Burris S, Vernick JS, Ditzler A, Strathdee S. The legality of selling or giving syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S13\u20138.","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"249_CR3","unstructured":"The Global Fund to Fight AIDS, Tuberculosis and Malaria. Global fund overview. Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria. n.d. [cited 2017 March 2]. Available from: \n                    http:\/\/www.theglobalfund.org\/en\/overview\/"},{"key":"249_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugpo.2015.08.001","volume":"27","author":"J Bridge","year":"2016","unstructured":"Bridge J, Hunter BM, Albers E, Cook C, Guarinieri M, Lazarus JV, et al. The Global Fund to Fight AIDS, Tuberculosis and Malaria\u2019s investments in harm reduction through the rounds-based funding model (2002\u20132014). Int J Drug Policy. 2016;27:132\u20137.","journal-title":"Int J Drug Policy"},{"key":"249_CR5","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.drugpo.2014.09.001","volume":"26","author":"SA Strathdee","year":"2015","unstructured":"Strathdee SA, Beletsky L, Kerr THIV. Drugs and the legal environment. Int J Drug Policy. 2015;26:S27\u201332.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"249_CR6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/j.1360-0443.2010.02976.x","volume":"105","author":"GV Bobashev","year":"2010","unstructured":"Bobashev GV, Zule WA. Modeling the effect of high dead-space syringes on the human immunodeficiency virus (HIV) epidemic among injecting drug users. Addiction. 2010;105(8):1439\u201347.","journal-title":"Addiction"},{"issue":"7","key":"249_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1086\/656212","volume":"202","author":"E Paintsil","year":"2010","unstructured":"Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202(7):984\u201390.","journal-title":"J Infect Dis"},{"issue":"1","key":"249_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugpo.2012.10.006","volume":"24","author":"P Vickerman","year":"2013","unstructured":"Vickerman P, Martin NK, Hickman M. Could low dead-space syringes really reduce HIV transmission to low levels? Int J Drug Policy. 2013;24(1):8\u201314.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"249_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2013.763554","volume":"45","author":"I Kirtadze","year":"2013","unstructured":"Kirtadze I, Otiashvili D, O\u2019Grady KE, Zule W, Krupitsky E, Wechsberg WM, et al. Twice stigmatized: provider\u2019s perspectives on drug-using women in the Republic of Georgia. J Psychoactive Drugs. 2013;45(1):1\u20139.","journal-title":"J Psychoactive Drugs"},{"key":"249_CR10","unstructured":"World Health Organization. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization; 2012."},{"key":"249_CR11","first-page":"9244504375","volume-title":"WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users\u20132012 revision","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users\u20132012 revision; 2012. p. 9244504375."},{"key":"249_CR12","unstructured":"World Health Organization. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Annex 8: values and preferences report. Geneva: World Health Organization; 2012."},{"issue":"1","key":"249_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12954-017-0207-5","volume":"15","author":"WA Zule","year":"2018","unstructured":"Zule WA, Pande PG, Otiashvili D, Bobashev GV, Friedman SR, Gyarmathy VA, et al. Options for reducing HIV transmission related to the dead space in needles and syringes. Harm Reduction J. 2018;15(1):3.","journal-title":"Harm Reduction J"},{"issue":"11","key":"249_CR14","doi-asserted-by":"publisher","first-page":"e0139737","DOI":"10.1371\/journal.pone.0139737","volume":"10","author":"M Binka","year":"2015","unstructured":"Binka M, Paintsil E, Patel A, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes is dependent on the design of the syringe-needle and dead space volume. PLoS One. 2015;10(11):e0139737.","journal-title":"PLoS One"},{"key":"249_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/aid.2016.0023","volume":"32","author":"N Abdala","year":"2016","unstructured":"Abdala N, Patel A, Heimer R. Recovering infectious HIV from novel syringe-needle combinations with low dead space volumes. AIDS Res Hum Retrovir. 2016;32:947\u201354.","journal-title":"AIDS Res Hum Retrovir."},{"key":"249_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12954-015-0069-7","volume":"12","author":"WA Zule","year":"2015","unstructured":"Zule WA, Latypov A, Otiashvili D, Kirtadze I, Ibragimov U, Bobashev GV. Factors that influence the characteristics of needles and syringes used by people who inject drugs in Tajikistan. Harm reduction journal. 2015;12:37.","journal-title":"Harm reduction journal"},{"issue":"6","key":"249_CR17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.drugpo.2014.09.011","volume":"25","author":"A Latypov","year":"2014","unstructured":"Latypov A, Otiashvili D, Zule W. Drug scene, drug use and drug-related health consequences and responses in Kulob and Khorog, Tajikistan. Int J Drug Policy. 2014;25(6):1204\u201314.","journal-title":"Int J Drug Policy"},{"key":"249_CR18","unstructured":"Ministry of Health and Social Protection of the Population of the Republic of Tajikistan & Republican AIDS Center. UNAIDS country progress report, 2016. Dushanbe: MHSPPRT & Republican AIDS Center. p. 2016."},{"key":"249_CR19","unstructured":"Rogers EM. Diffusion of innovations. 4th. New York: Free Press; 1995. xvii, 519 p. p."},{"key":"249_CR20","first-page":"xiii, 617","volume-title":"Social foundations of thought and action : a social cognitive theory","author":"A Bandura","year":"1986","unstructured":"Bandura A. Social foundations of thought and action : a social cognitive theory. Englewood Cliffs: Prentice-Hall; 1986. p. xiii, 617."},{"issue":"3","key":"249_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00042560-199703010-00015","volume":"14","author":"WA Zule","year":"1997","unstructured":"Zule WA, Ticknor-Stellato KM, Desmond DP, Vogtsberger KN. Evaluation of needle and syringe combinations. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(3):294\u20135.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"249_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.drugpo.2016.09.005","volume":"39","author":"JM Kesten","year":"2017","unstructured":"Kesten JM, Ayres R, Neale J, Clark J, Vickerman P, Hickman M, et al. Acceptability of low dead space syringes and implications for their introduction: a qualitative study in the West of England. Int J Drug Polic. 2017;39:99\u2013108.","journal-title":"Int J Drug Polic"},{"key":"249_CR23","first-page":"xxi, 623","volume-title":"Experimental and quasi-experimental designs for generalized causal inference","author":"WR Shadish","year":"2001","unstructured":"Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Boston: Houghton Mifflin; 2001. p. xxi, 623."},{"issue":"7","key":"249_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0277-9536(01)00256-8","volume":"55","author":"WA Zule","year":"2002","unstructured":"Zule WA, Desmond DP, Neff JA. Syringe type and drug injector risk for HIV infection: a case study in Texas. Soc Sci Med. 2002;55(7):1103\u201313.","journal-title":"Soc Sci Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0249-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-018-0249-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0249-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:10:11Z","timestamp":1589541011000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-018-0249-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1186\/s12954-018-0249-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"19 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Committee of Medical Ethics of Tajikistan and the RTI International Office of Human Research Protection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Exchange Supplies donated the LDS needles, but Exchange Supplies had no other involvement in the study. No one at Exchange Supplies reviewed or had any input regarding this paper or any findings from the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"44"}}